Multispecific t cell engager polypeptides in combination with t cells for cancer therapy
AssigneeThe Brigham and Women's Hospital, Inc.
InventorsKhalid SHAH, Filippo ROSSIGNOLI
Life of this patent
Estimating the term…
Abstract
This technology describes novel cell based combined therapeutic modalities that include a stem cell engineered to secrete a multispecific T cell engager (MiTE) polypeptide construct and an isolated population of T cells that are autologous to the subject.
Claims30
A method of treating cancer, the method comprising administering to a subject in need thereof:
- a) a stem cell or immune cell engineered to secrete a multispecific T cell engager (MITE) polypeptide construct;
- and
- b) an isolated population of T cells that are autologous to the subject.
6-7. (canceled)
-12. (canceled)
-17. (canceled)
(canceled)
-25. (canceled)
-30. (canceled)
A composition comprising a stem cell engineered to express first and second MiTE polypeptides.
-38. (canceled)
-48. (canceled)
A composition comprising a stem cell engineered to express first and second MiTE polypeptides and an isolated population of T cells.
-57. (canceled)
-61. (canceled)
Dependencies are inferred from the claim text.